Balyasny Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.64M | Sell |
35,130
-11,973
| -25% | -$2.66M | 0.01% | 1156 |
|
|
2025
Q4 | $10.8M | Sell |
47,103
-13,382
| -22% | -$3.05M | 0.01% | 987 |
|
|
2025
Q3 | $14M | Sell |
60,485
-1,233,299
| -95% | -$251M | 0.02% | 886 |
|
|
2025
Q2 | $240M | Buy |
1,293,784
+1,266,047
| +4,564% | +$235M | 0.36% | 38 |
|
|
2025
Q1 | $5.81M | Buy |
27,737
+10,284
| +59% | +$2M | 0.01% | 1174 |
|
|
2024
Q4 | $3.1M | Buy |
+17,453
| New | +$3.21M | ﹤0.01% | 1495 |
|
|
2024
Q3 | – | Sell |
-8,254
| Closed | -$1.54M | – | 2680 |
|
|
2024
Q2 | $1.42M | Sell |
8,254
-5,983
| -42% | -$991K | ﹤0.01% | 1656 |
|
|
2024
Q1 | $2.59M | Sell |
14,237
-59,775
| -81% | -$10.3M | ﹤0.01% | 1464 |
|
|
2023
Q4 | $11.5M | Sell |
74,012
-175,999
| -70% | -$25.7M | 0.02% | 812 |
|
|
2023
Q3 | $37.3M | Sell |
250,011
-463,248
| -65% | -$68M | 0.08% | 360 |
|
|
2023
Q2 | $96.1M | Buy |
713,259
+260,079
| +57% | +$38.1M | 0.21% | 107 |
|
|
2023
Q1 | $72.2M | Sell |
453,180
-419,818
| -48% | -$64.2M | 0.18% | 128 |
|
|
2022
Q4 | $141M | Buy |
872,998
+701,963
| +410% | +$108M | 0.39% | 44 |
|
|
2022
Q3 | $23M | Buy |
171,035
+164,730
| +2,613% | +$23.6M | 0.07% | 386 |
|
|
2022
Q2 | $966K | Sell |
6,305
-167,048
| -96% | -$25.5M | ﹤0.01% | 1773 |
|
|
2022
Q1 | $28.1M | Sell |
173,353
-198
| -0.1% | -$28.8K | 0.09% | 316 |
|
|
2021
Q4 | $23.5M | Buy |
173,551
+152,643
| +730% | +$18M | 0.08% | 347 |
|
|
2021
Q3 | $2.25M | Buy |
+20,908
| New | +$2.39M | 0.01% | 1087 |
|
|
2020
Q3 | – | Sell |
-61,000
| Closed | -$5.99M | – | 1249 |
|
|
2020
Q2 | $5.99M | Sell |
61,000
-526,189
| -90% | -$46.3M | 0.05% | 468 |
|
|
2020
Q1 | $44.7M | Buy |
587,189
+555,525
| +1,754% | +$47.3M | 0.53% | 28 |
|
|
2019
Q4 | $2.8M | Buy |
+31,664
| New | +$2.63M | 0.02% | 689 |
|
|
2019
Q3 | – | Sell |
-46,884
| Closed | -$3.41M | – | 1112 |
|
|
2019
Q2 | $3.41M | Sell |
46,884
-33,372
| -42% | -$2.62M | 0.02% | 722 |
|
|
2019
Q1 | $6.47M | Buy |
80,256
+27,297
| +52% | +$2.23M | 0.04% | 507 |
|
|
2018
Q4 | $4.88M | Buy |
52,959
+3,905
| +8% | +$343K | 0.04% | 510 |
|
|
2018
Q3 | $4.64M | Buy |
49,054
+38,237
| +353% | +$3.63M | 0.02% | 727 |
|
|
2018
Q2 | $1M | Sell |
10,817
-429,683
| -98% | -$42M | ﹤0.01% | 1131 |
|
|
2018
Q1 | $41.7M | Buy |
440,500
+231,273
| +111% | +$25.4M | 0.17% | 158 |
|
|
2017
Q4 | $20.2M | Sell |
209,227
-720,172
| -77% | -$67.9M | 0.06% | 405 |
|
|
2017
Q3 | $82.6M | Sell |
929,399
-554,448
| -37% | -$42.2M | 0.32% | 63 |
|
|
2017
Q2 | $108M | Buy |
1,483,847
+1,280,997
| +631% | +$86.1M | 0.44% | 36 |
|
|
2017
Q1 | $13.2M | Buy |
202,850
+197,750
| +3,877% | +$12.4M | 0.06% | 400 |
|
|
2016
Q4 | $319K | Sell |
5,100
-1,731
| -25% | -$106K | ﹤0.01% | 1212 |
|
|
2016
Q3 | $431K | Buy |
6,831
+3,453
| +102% | +$224K | ﹤0.01% | 764 |
|
|
2016
Q2 | $209K | Sell |
3,378
-6,182
| -65% | -$377K | ﹤0.01% | 1022 |
|
|
2016
Q1 | $546K | Sell |
9,560
-1,317,944
| -99% | -$73.5M | ﹤0.01% | 874 |
|
|
2015
Q4 | $78.6M | Buy |
1,327,504
+387,083
| +41% | +$22.3M | 0.55% | 34 |
|
|
2015
Q3 | $51.2M | Buy |
940,421
+503,756
| +115% | +$32.8M | 0.38% | 65 |
|
|
2015
Q2 | $29.3M | Sell |
436,665
-421,919
| -49% | -$27.5M | 0.18% | 147 |
|
|
2015
Q1 | $50.3M | Buy |
+858,584
| New | +$51.9M | 0.41% | 56 |
|
|
2013
Q3 | – | Sell |
-125,000
| Closed | -$5.17M | – | 556 |
|
|
2013
Q2 | $5.17M | Buy |
+125,000
| New | +$5.47M | 0.09% | 281 |
|
Other funds holding ABBV
VCM
VPM
Balyasny Asset Management's ABBV Position: Q1 2026 in Review
Balyasny Asset Management reduced its AbbVie (ABBV) stake by 25% in Q1 2026, selling an estimated $2.66M and leaving 35,130 shares worth $7.64M. The position accounts for 0.01% of the portfolio, ranked #1156.
Balyasny Asset Management first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. The position peaked at $240M in Q2 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Balyasny Asset Management held 35,130 shares of AbbVie worth $7.64M as of Q1 2026.
- Balyasny Asset Management sold 11,973 AbbVie shares in Q1 2026, an estimated $2.66M.
- AbbVie made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1156 holding.
- Balyasny Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
- Balyasny Asset Management's AbbVie position peaked at $240M in Q2 2025.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.